View Older Stories View More Recent Stories

Apr 27, 2021 04:01PM Amgen Reports First Quarter 2021 Financial Results
Apr 23, 2021 04:00PM Amgen's (AMGN) OTEZLA Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis
Apr 23, 2021 04:00PM OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis
Apr 22, 2021 04:00PM Amgen Announces Webcast Of 2021 First Quarter Financial Results
Apr 22, 2021 01:01AM Press release Biocartis Group NV: BIOCARTIS Q1 2021 BUSINESS UPDATE
Apr 19, 2021 04:01PM Amgen (AMGN) Granted FDA Breakthrough Therapy Designation for Bemarituzumab
Apr 19, 2021 04:00PM Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
Apr 19, 2021 07:00AM Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
Apr 16, 2021 08:29AM Amgen (AMGN) Successfully Completes Acquisition Of Five Prime Therapeutics (FPRX)
Apr 16, 2021 08:25AM Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
Mar 30, 2021 04:01PM Amgen (AMGN) to Acquire Rodeo Therapeutics for $55M Upfront and Up to $666M Additional Cash
Mar 30, 2021 04:00PM Amgen to Acquire Rodeo Therapeutics Corporation
Mar 11, 2021 04:00PM Amgen To Present At The Oppenheimer 31st Annual Healthcare Conference
Mar 4, 2021 08:31AM Amgen (AMGN) To Acquire Five Prime Therapeutics (FPRX) For $1.9 Billion in Cash, $38/share
Mar 4, 2021 08:30AM Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash
Mar 4, 2021 08:30AM Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
Mar 3, 2021 04:00PM Amgen Announces 2021 Second Quarter Dividend
Mar 2, 2021 04:00PM Amgen (AMGN) Announces BLINCYTO Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
Mar 2, 2021 04:00PM BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
Feb 26, 2021 09:07AM Amgen (AMGN), AstraZeneca (AZN) Say Tezepelumab Is First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
Feb 26, 2021 09:00AM Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
Feb 24, 2021 04:00PM Amgen To Present At The Cowen 41st Annual Healthcare Conference
Feb 22, 2021 04:00PM Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting
Feb 22, 2021 09:02AM Amgen (AMGN) Submits sNDA for Otezla for Adults with Mild-To-Moderate Plaque Psoriasis
Feb 22, 2021 09:00AM Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis
Feb 16, 2021 04:00PM Amgen (AMGN) Announces FDA Grants Sotorasib Priority Review Designation For Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic NSCLC
Feb 16, 2021 04:00PM FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Feb 9, 2021 04:00PM Amgen To Present At Guggenheim Healthcare Talks Oncology Day
Feb 3, 2021 04:00PM Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups
Feb 2, 2021 04:01PM Amgen Reports Fourth Quarter And Full Year 2020 Financial Results
Jan 29, 2021 04:00PM Amgen (AMGN) Announces Breakthrough Therapy Designation Granted For Sotorasib In China
Jan 29, 2021 04:00PM Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China
Jan 28, 2021 04:00PM Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results
Jan 28, 2021 02:36PM Amgen (AMGN) Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced NSCLC
Jan 28, 2021 02:35PM Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Jan 26, 2021 04:00PM Amgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer
Jan 12, 2021 09:00AM Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020
Jan 11, 2021 04:45PM Amgen To Achieve Carbon Neutrality By 2027
Jan 6, 2021 04:00PM Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference
Dec 22, 2020 04:00PM Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health
Dec 22, 2020 09:01AM Amgen (AMGN) Submits Sotorasib MAA To The European Medicines Agency
Dec 22, 2020 09:00AM Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency
Dec 22, 2020 06:10AM Amgen (AMGN), AstraZeneca (AZN) Report SOURCE Phase 3 Trial For Tezepelumab Did Not Meet Primary Endpoint in
Dec 22, 2020 06:10AM Amgen (AMGN), AstraZeneca (AZN) Report SOURCE Phase 3 Trial For Tezepelumab Did Not Meet Primary Endpoint in
Dec 22, 2020 02:00AM Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Dec 17, 2020 04:10PM Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral
Dec 17, 2020 04:00PM Amgen (AMGN) Confirms FDA Approves its RIABNI, A Biosimilar To Rituxan (rituximab)
Dec 17, 2020 04:00PM FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
Dec 16, 2020 05:00PM Amgen To Transfer Listing Of Debt Securities To Nasdaq
Dec 16, 2020 04:30PM Amgen Announces 10% Increase In 2021 First Quarter Dividend
View More Recent Stories View Older Stories